On March 6, 2026, a biopharmaceutical company dedicated to the discovery and development of innovative therapies for metabolic diseases announced that Enoglutide Injection (Xianweiying)—the world’s first cAMP-biased GLP-1 receptor agonist—has received market approval from the National Medical Products Administration (NMPA). It is indicated for the long-term weight management of overweight or obese adults, to be used in conjunction with a reduced-calorie diet and increased physical activity.